Oxfam report "Investing for Life": Company responses

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses... - Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis responded - Roche, Eli Lilly declined to respond - Bristol-Myers Squibb, Wyeth did not respond

Chronologie

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Fév 2008

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

19 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

18 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

18 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Déc 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Oxfam report "Investing for Life": Company responses

Date:

12 Déc 2007

Type de contenu:

Article

Langues disponibles: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Date:

27 Nov 2007

Type de contenu:

Article

Langues disponibles: español
Oxfam says top drug companies focusing on patents, not poor

Date:

26 Nov 2007

Type de contenu:

Article

Langues disponibles: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Date:

23 Nov 2007

Type de contenu:

Article
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Date:

12 Nov 2007

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Date:

1 Nov 2007

Type de contenu:

Article

Langues disponibles: English

Voir l'affaire complète

Charger plus Voir moins

Business & Human Rights
Resource Centre

Centre de Ressources sur les Entreprises et les Droits de l'Homme

Cette page n’est pas disponible en Français et est affichée en English

Oxfam report "Investing for Life": Company responses

Chronologie

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices